CanSino Biologics Inc. (HKG:6185)
Hong Kong
· Delayed Price · Currency is HKD 36.45
-0.80 (-2.15%)
Mar 3, 2025, 4:08 PM HKT
CanSino Biologics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2016 |
| Operating Revenue | 846.34 | 345.18 | 1,031 | 4,300 | 18.54 | Upgrade
|
| Other Revenue | - | 11.9 | 3.55 | - | 6.35 | Upgrade
|
| Revenue | 846.34 | 357.08 | 1,035 | 4,300 | 24.89 | Upgrade
|
| Revenue Growth (YoY) | 137.01% | -65.49% | -75.94% | 17174.82% | 990.05% | Upgrade
|
| Cost of Revenue | - | 800.83 | 1,218 | 1,298 | 14.73 | Upgrade
|
| Gross Profit | 846.34 | -443.75 | -183.71 | 3,002 | 10.16 | Upgrade
|
| Selling, General & Admin | - | 639.88 | 535.48 | 327.14 | 95.43 | Upgrade
|
| Research & Development | - | 637.99 | 778.26 | 878.72 | 428.49 | Upgrade
|
| Other Operating Expenses | 1,222 | -14.16 | -7.24 | 10.18 | 3.91 | Upgrade
|
| Operating Expenses | 1,222 | 1,279 | 1,315 | 1,218 | 527.83 | Upgrade
|
| Operating Income | -375.22 | -1,723 | -1,499 | 1,784 | -517.67 | Upgrade
|
| Interest Expense | - | -64.15 | -41.34 | -20.42 | - | Upgrade
|
| Interest & Investment Income | - | 173.26 | 161.89 | 125.42 | 63.76 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 20.58 | 160.64 | -33.78 | -27.36 | Upgrade
|
| Other Non Operating Income (Expenses) | -5.98 | -106.07 | -0.49 | -0.28 | -0.14 | Upgrade
|
| EBT Excluding Unusual Items | -381.2 | -1,699 | -1,218 | 1,855 | -481.41 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -14.56 | -4.06 | 71.09 | 6.64 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.18 | - | - | - | Upgrade
|
| Asset Writedown | - | -363.03 | -0.25 | -0.25 | -0.14 | Upgrade
|
| Other Unusual Items | - | 96.79 | 38.59 | 10.93 | 78.27 | Upgrade
|
| Pretax Income | -381.2 | -1,979 | -1,184 | 1,937 | -396.64 | Upgrade
|
| Income Tax Expense | -2.32 | -12.07 | -219.24 | 29.7 | - | Upgrade
|
| Earnings From Continuing Operations | -378.88 | -1,967 | -964.76 | 1,907 | -396.64 | Upgrade
|
| Minority Interest in Earnings | - | 484.7 | 55.33 | 7.3 | - | Upgrade
|
| Net Income | -378.88 | -1,483 | -909.43 | 1,914 | -396.64 | Upgrade
|
| Net Income to Common | -378.88 | -1,483 | -909.43 | 1,914 | -396.64 | Upgrade
|
| Shares Outstanding (Basic) | 248 | 247 | 247 | 247 | 231 | Upgrade
|
| Shares Outstanding (Diluted) | 248 | 247 | 247 | 247 | 231 | Upgrade
|
| Shares Change (YoY) | 0.38% | -0.17% | -0.08% | 7.26% | 11.79% | Upgrade
|
| EPS (Basic) | -1.53 | -6.01 | -3.68 | 7.74 | -1.72 | Upgrade
|
| EPS (Diluted) | -1.53 | -6.01 | -3.68 | 7.74 | -1.72 | Upgrade
|
| Free Cash Flow | - | -1,519 | -2,927 | 846.86 | -638.23 | Upgrade
|
| Free Cash Flow Per Share | - | -6.16 | -11.84 | 3.42 | -2.77 | Upgrade
|
| Dividend Per Share | - | - | - | 0.800 | - | Upgrade
|
| Gross Margin | 100.00% | -124.27% | -17.76% | 69.82% | 40.82% | Upgrade
|
| Operating Margin | -44.33% | -482.38% | -144.89% | 41.49% | -2079.82% | Upgrade
|
| Profit Margin | -44.77% | -415.23% | -87.90% | 44.52% | -1593.56% | Upgrade
|
| Free Cash Flow Margin | - | -425.31% | -282.87% | 19.70% | -2564.19% | Upgrade
|
| EBITDA | -134.84 | -1,482 | -1,319 | 1,849 | -498.75 | Upgrade
|
| EBITDA Margin | -15.93% | - | -127.47% | 43.01% | - | Upgrade
|
| D&A For EBITDA | 240.39 | 240.39 | 180.13 | 65.11 | 18.91 | Upgrade
|
| EBIT | -375.22 | -1,723 | -1,499 | 1,784 | -517.67 | Upgrade
|
| EBIT Margin | -44.33% | - | -144.89% | 41.49% | - | Upgrade
|
| Effective Tax Rate | - | - | - | 1.53% | - | Upgrade
|
| Revenue as Reported | - | 357.08 | 1,035 | 4,300 | 24.89 | Upgrade
|
| Advertising Expenses | - | - | - | 9.03 | 0.3 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.